The first orally bioavailable BCL-XL-selective inhibitor A-1331852 demonstrated modest single-agent activity in NSCLC, mesothelioma, breast, ovarian and colorectal cancer xenograft models [8,11,22]. This evidence concerns the gene BCL2L1 and non-small cell lung carcinoma.